Lindsey Shapiro, PhD, science writer —

Lower urinary cortisol levels at the start of treatment with Recorlev (levoketoconazole) are associated with higher rates of cortisol normalization among people with endogenous Cushing’s syndrome, according to new analyses from a Phase 3 clinical trial. Patients with lower starting cortisol levels also require lower maintenance doses of Recorlev…

CRN04894, now being called atumelnant, quickly lowered urine cortisol levels in five people with ACTH-dependent Cushing’s syndrome taking part in a clinical trial, according to interim study findings. The open-label Phase 1b/2a trial (NCT05804669), which is being conducted at the National Institutes of Health (NIH) in Maryland, still…

Reaching a prompt diagnosis of Cushing’s syndrome and managing it appropriately during pregnancy are critical for minimizing the condition’s harmful effects on the mother and her child, according to case series that followed five women who gave birth at a clinic in Australia. The series also highlighted the challenges of…

Analyzing the levels of a molecule called S1P — fully known as sphingosine-1-phosphate — in the tissue surrounding a pituitary gland tumor in Cushing’s disease patients can help determine the side of the gland on which the tumor is located. That’s according to a study that made use of…

Alterations in the activity of a signaling system called RAAS in fatty tissue could contribute to high blood pressure in people with Cushing’s syndrome, according to a recent report. Data showed gene activity associated with renin-angiotensin-aldosterone-system (RAAS) was altered in fatty tissue from Cushing’s patients relative to people without the…

Surgery to remove a tumor in the brain’s pituitary gland cured about a third of people with Cushing’s disease in a recent Thai study, a remission rate markedly lower than the 80-90% rate reported in other studies. Researchers believe the low rate might have been due to some surgeries…

Long-term treatment with Isturisa (osilodrostat) led to a sustained normalization in cortisol levels, symptom relief, and improved quality of life for people with Cushing’s disease, according to the full results from the LINC 4 clinical trial and its extension phase. “These data provide further evidence of the durable clinical…

The Phase 3 GRACE trial testing relacorilant in people with Cushing’s syndrome has completed enrollment and data from it is expected next year, according to a recent corporate update from Corcept Therapeutics, its developer. The company plans to submit a new drug application (NDA) to U.S. authorities to market…

People with Cushing’s syndrome, including those with Cushing’s disease, exhibit immune system alterations that could contribute to some symptoms of the disease, a small study suggests. Analyses of immune cells from Cushing’s patients indicated signs of both systemic (whole body) inflammation as well as immunosuppression, which scientists believe might…

The accuracy of late-night testing of cortisol levels in saliva — a common test for diagnosing Cushing’s syndrome — may be lower in real-world clinical practice than in controlled experimental settings, according to a new study from Turkey. The results showed the sensitivity, or true positive rate, of the late-night…